Morishita Jintan Co., Ltd. (4524) AI Stock Analysis

• Market Cap: ¥9.01B
• Dividend Yield: 2.55%
• Average Volume (3M): 1.86K
• Price to Earnings (P/E): 19.4
• Beta (1Y): 0.47
• Revenue Growth: 2.90%
• EPS Growth: -21.60%
• Country: JP
• Employees: 354
• Sector: Healthcare
• Sector Strength: 37
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 39.84
• Shares Outstanding: 4,150,000
• 10 Day Avg. Volume: 2,290
• 30 Day Avg. Volume: 1,863
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥2,434.00
• Price Target Upside: 11.50% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 78 Outperform
• Price Target: ¥2,434.00 ▲(11.50% Upside)

Morishita Jintan Co., Ltd. receives a strong score driven by its solid financial performance, highlighted by robust revenue growth and a strong balance sheet. Technical analysis supports a positive trend, although caution is advised as the stock approaches overbought conditions. Valuation is reasonable with a fair P/E ratio and attractive dividend yield. The absence of recent earnings call insights or corporate events slightly limits the overall evaluation.

Morishita Jintan Co., Ltd. Business Overview & Revenue Model

Company Description

Morishita Jintan Co., Ltd. is a Japanese company operating primarily in the pharmaceutical and health-related industries. Founded in 1893, the company is known for its development, production, and distribution of a wide range of healthcare products. These include pharmaceuticals, health supplements, and oral care products. Morishita Jintan has built a reputation for innovation, particularly in the field of encapsulation technology, which is used to deliver active ingredients effectively in their products.

How the Company Makes Money

Morishita Jintan Co., Ltd. generates revenue through several key streams. The primary source of income is the sale of its pharmaceutical products, which includes both over-the-counter medications and prescription drugs. Additionally, the company earns from its health supplements, which are marketed for various health benefits such as digestive health and general wellness. The company's oral care products, including toothpastes and mouthwashes, also contribute to its revenue. A significant factor in its earnings is the use of advanced encapsulation technology that enhances the efficacy and delivery of its products, thereby adding value. Morishita Jintan also benefits from strategic partnerships and collaborations with other firms in the healthcare sector, which help in expanding its market reach and product portfolio.

Morishita Jintan Co., Ltd. Financial Statement Overview

Summary

Morishita Jintan Co., Ltd. exhibits solid financial health with growth in revenues and effective cost management leading to strong margins. The balance sheet strength is highlighted by low leverage and high equity, while cash flow management shows improvement in free cash flow. Overall, the company is well-positioned for sustained financial performance, though attention should be given to maintaining net profit margins.

Income Statement

Morishita Jintan Co., Ltd. demonstrates robust revenue growth over the years, with a notable increase from 2022 to 2025. The company maintains a healthy gross profit margin, indicative of efficient production and pricing strategies. However, the net profit margin saw a decline in 2025, suggesting increased operational costs or other expenses. EBIT and EBITDA margins remain strong, underscoring operational efficiency.

Balance Sheet

The company has a strong balance sheet with a high equity ratio, reflecting financial stability and low reliance on debt financing. The debt-to-equity ratio is low, indicating prudent financial management. Return on equity is healthy, showcasing effective use of shareholder funds to generate profits.

Cash Flow

Operating cash flow has generally been positive, showing good cash generation from core operations. Free cash flow fluctuated, with a significant recovery in 2025, hinting at improved capital expenditure management. The operating cash flow to net income ratio is favorable, suggesting good cash conversion efficiency.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	12.64B	12.77B	12.41B	11.36B	9.56B	9.43B
Gross Profit	5.67B	5.79B	6.00B	5.31B	4.88B	4.79B
EBITDA	742.50M	1.36B	1.29B	1.20B	885.00M	814.00M
Net Income	312.00M	547.00M	697.00M	491.00M	283.00M	206.00M
Balance Sheet
Total Assets	17.65B	17.90B	17.18B	16.10B	14.48B	14.45B
Cash, Cash Equivalents and Short-Term Investments	1.17B	1.94B	1.09B	2.41B	2.14B	2.70B
Total Debt	1.15B	1.36B	425.00M	537.00M	786.00M	1.30B
Total Liabilities	5.29B	5.74B	5.04B	4.71B	4.03B	4.17B
Stockholders Equity	12.35B	12.15B	12.14B	11.39B	10.45B	10.27B
Cash Flow
Free Cash Flow	0.00	69.00M	-455.00M	715.00M	-159.00M	284.00M
Operating Cash Flow	0.00	669.00M	196.00M	1.18B	543.00M	871.00M
Investing Cash Flow	0.00	-701.00M	-1.15B	-474.00M	-463.00M	-502.00M
Financing Cash Flow	0.00	880.00M	-362.00M	-433.00M	-645.00M	-141.00M

Morishita Jintan Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2183.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4524, the sentiment is Positive. The current price of 2183 is above the 20-day moving average (MA) of 2173.25, above the 50-day MA of 2140.80, and above the 200-day MA of 2092.20, indicating a bullish trend. The MACD of 20.12 indicates Negative momentum. The RSI at 72.22 is Negative, neither overbought nor oversold. The STOCH value of 99.07 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4524.

Morishita Jintan Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4524	78 Outperform	¥9.01B	19.44		2.55%	2.90%	-21.60%
4539	70 Outperform	¥5.68B	14.38		3.25%	5.18%	―
Sector *	60 Neutral	HK$17.66B	4.47	-4.95%	3.59%	9.78%	-39.36%
4582	51 Neutral	¥7.60B	―		―	-56.12%	-73.82%
4512	49 Neutral	¥10.55B	159.96		0.98%	4.00%	-933.04%
4892	44 Neutral	¥5.93B	―		―	4.83%	-21.44%
4586	41 Neutral	¥4.00B	―		―	773.28%	35.71%